Webinar: Advancing TB vaccines in the time of COVID-19
Advancing TB vaccines in the time of COVID-19
This is a preliminary program and is subject to change - Revised 18 March 2021
Tuesday
20 April 2021
09:00 – 10:00 EDT OPENING SESSION
Co-Chairs: Nick Drager, TBVI (Switzerland) | Mark Feinberg, IAVI (USA) | David Lewinsohn,
Working Group on New TB Vaccines (USA)
Welcome and Opening Remarks
Nick Drager, TBVI
Mark Feinberg, IAVI
David Lewinsohn, Working Group on New TB Vaccines
Keynote Address
Helen Rees, Wits RHI, Wits University (South Africa)
Other speakers to be announced
10:00 – 10:15 BREAK
10:15 – 11:45 SCIENTIFIC SESSION: NOVEL INSIGHTS AND APPROACHES TO TB VACCINE R&D
Co-Chairs: Willem Hanekom, Africa Health Research Institute (South Africa) | Huang Huang,
Stanford University (USA)
Part I: Granulomas: Novel insights into an ancient structure
Visualizing immunosuppressive microenvironments in Mycobacterium tuberculosis
granulomas
Michael Gerner, University of Washington (USA)
Insights into features of bacterial control from single cell profiling of TB granulomas
Hannah Priyadarshini Gideon, University of Pittsburgh School of Medicine (USA)
Part 2: Novel Insights into protective immunity
Protective role of Th17 immunity – title to be confirmed
Andrea Cooper, University of Leicester (UK)
B cells and antibodies – title to be confirmed
Lenette Lu, University of Texas Southwestern Medical Center (USA)
Part 3: Novel vaccine delivery platform
RNA vaccines – title to be confirmed
Mustafa Diken, BioNTech (Germany)
11:45 – 12:00 BREAK
12:00 – 13:30 SKILL-BUILDING WORKSHOP: TRANSFORMING YOUR PITCH INTO A GRANT
Co-Chairs: Sara Suliman, Brigham & Women’s Hospital (USA) | David Lewinsohn, Working
Group on New TB Vaccines and Oregon Health & Science University (USA)
Overview presentation – title to be confirmed
Katrin Eichelberg, NIAID/NIH (USA)
Breakout Sessions
• Immunology: Elisa Nemes and Virginie Rozot, South African Tuberculosis Vaccine
Initiative, University of Cape Town (South Africa)
• Clinical Research: Ann Ginsberg, Bill & Melinda Gates Foundation (USA), Simon
Mendelsohn, South African Tuberculosis Vaccine Initiative, University of Cape Town (South
Africa)
• Epidemiology: Richard White, London School of Hygiene and Tropical Medicine (UK), Puck
Pelzer, KNCV Tuberculosis Foundation (Netherlands)
This is a preliminary program and is subject to change - Revised 18 March 2021
Wednesday
21 April 2021
9:00 – 10:30 SCIENTIFIC SESSION: CLINICAL DEVELOPMENT OF NEW TB VACCINES
Format: Co-Chairs: Ann Ginsberg, Bill & Melinda Gates Foundation (USA) | Monde Muyoyeta, CIDRZ
(Zambia)
Advancing TB vaccine candidates in the clinic
Ann Ginsberg, Bill & Melinda Gates Foundation (USA)
From TB to COVID and back again: Public involvement as an essential science
Anastasia Koch and Cheleka Mpande, Eh!woza (South Africa)
Updates on candidates in late-stage development
Update on development activities for M72/ASO1E
Alexander Schmidt, Bill & Melinda Gates Medical Research Institute (USA)
The DAR-901 prevention of infection trial
C. Fordham von Reyn, Dartmouth Geisel School of Medicine (USA)
MTBVAC – title to be confirmed
Ingrid Murillo, Biofabri (Spain)
The tuberculosis vaccine H56:IC31
Álvaro Borges, Statens Serum Institut (Denmark)
A brief update on the VPM1002 vaccine candidate
Sajjad Desai, Serum Institute of India (India)
10:30 – 10:45 BREAK
10:45 – 11:45 PANEL DISCUSSION: POLICY AND ACCESS ISSUES FOR TB VACCINES
Co-Chairs: Alejandro Cravioto, Universidad Nacional Autónoma de México (Mexico) | Shelly
Malhotra (IAVI)
Overview Presentation – title to be confirmed
Shelly Malhotra, IAVI (USA)
Panel Discussion
• Evaline Kibuchi, Stop TB Partnership Kenya (Kenya)
• Jeremiah Chakaya (Kenya)
• Cherise Scott, UNITAID (Switzerland)
Other panelists to be confirmed
11:45 – 12:00 BREAK
12:00 – 13:30 SKILL-BUILDING WORKSHOP: ADVOCACY FOR RESEARCHERS
This workshop is aimed at researchers who are interested in learning how they can contribute
their experience and their voice to advocate for TB vaccine research and development.
Speaker and program to be announced.
Thursday
22 April 2021
9:00 – 10:30 SCIENTIFIC SESSION: BCG, 100 YEARS LATER
Co-Chairs: Camille Locht, Institut Pasteur de Lille (France) | Puck Pelzer, KNCV Tuberculosis
Foundation (Netherlands)
BCG: What have we learnt in 100 years?
Helen McShane, University of Oxford (UK)
Trained immunity as a mechanism behind the wider applicability of BCG
Simone Joosten, Leiden University Medical Center (Netherlands)
BCG trials for COVID-19 and other upper respiratory infections – title to be announced
Nigel Curtis, Murdoch Children’s Research Institute (Australia)
PRELIMINARY PROGRAM DRAFT – NOT FOR DISTRIBUTION 3 - Revised 18 March 2021
This is a preliminary program and is subject to change
BCG revaccination: examining potential public policy impact and value of POI endpoint –
title to be announced
Gavin Churchyard, Aurum Institute (South Africa)
Potential effect of disruptions to BCG vaccination on global paediatric tuberculosis
mortality
Richard White, London School of Hygiene and Tropical Medicine (UK)
10:30 – 10:45 BREAK
10:45 – 11:45 PANEL DISCUSSION: LEVERAGING COVID-19 TO ADVANCE TO VACCINE R&D
Co-Chairs: Gerald Voss, TBVI (Belgium) | To be announced
Overview Presentation – title to be confirmed
Gerald Voss, TBVI (Belgium)
Panel Discussion
• James Kublin, HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center
(USA)
• Erica Andersen-Nissen, Cape Town HVTN Immunology Laboratory (Cape Town)
Other panelists to be announced
11:45 – 12:00 BREAK
12:00 – 13:00 PANEL DISCUSSION: CLOSING THE FINANCING GAP FOR TB VACCINE R&D
Co-Chairs: Glaudina Loots, Department of Science and Technology (South Africa) – invited |
Mike Frick, Treatment Action Group (USA)
Overview Presentation
Mike Frick, Treatment Action Group (USA)
Panelists to be announced
13:00 – 13 :30 CLOSING SESSION
Session details to be announce